Peer-influenced content. Sources you trust. No registration required. This is HCN.

Neurology AdvisorSerum Neurofilament Light Chain (sNfl) in the Prognosis of Disease Activity in Relapsing Multiple Sclerosis

Panelists conclude that sNfL can be used as a biomarker to assess response to
treatment in future trials. In the clinic setting, it could become valuable in directing
therapy; for example, in cases in which the patient is absent clinical signs of aggressive
MS and it’s unclear if they will benefit from infused, injected, or oral disease-modifying

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form